NAPU Napo Pharm Di

    RNS Number : 9606F
  Napo Pharmaceuticals Inc
  16 October 2008
   

 For immediate release  16 October 2008


    Napo Pharmaceuticals, Inc
    ("Napo" or "the Company")
    CANCELLATION OF LISTING
    South San Francisco, California, 16 October, 2008 - Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) announces that its listing on the
Official List of the London Stock Exchange will be cancelled effective at 8:00 am 16 October 2008.
    Following this notification it is not anticipated that Napo shares will be traded on any public market. 
    For more information please contact: 
    Napo Pharmaceuticals, Inc. 
Lisa Conte, Chief Executive Officer 
+001 (650) 616-1902 
    Charles Thompson, Chief Financial Officer
+001 (650) 616-1902 
    Buchanan Communications 
Tim Anderson, Mary-Jane Johnson, Catherine Breen
(44) + 020 7466 5000 
    About Napo Pharmaceuticals, Inc. 
    Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in
collaboration with local partners. Napo was founded in November 2001, and is based in California, USA with a subsidiary in Mumbai, India. 
    Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in various stages of clinical development for four distinct
product indications, including a late-stage Phase 3 program: 
    *   CRO-HIV for AIDS diarrhea, Phase 3     *   CRO-IBS for diarrhea irritable bowel syndrome ("D-IBS"), Phase 2     *   CRO-ID for acute
infectious diarrhea (including cholera), Phase 2     *   CRO-PED for pediatric diarrhea, Phase 1     The FDA has granted fast-track status
to CRO-IBS and CRO-HIV. 
    Crofelemer, a proprietary patented first in class agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably
harvested from several countries in South America. Napo has exclusive worldwide rights to synthetic compounds in pre-clinical development
which act by the same mechanism of action. Napo also plans to develop an early clinical stage product, NP-500, for the treatment of insulin
resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome) and has 4 issued patents for anti-cancer
agents in pre-clinical development. Napo has a plant library of approximately 2,300 medicinal plants from tropical regions and Napo has
entered two screening relationships associated with this collection. Currently, products are based on the chemical and biological diversity
derived from plants with medicinal properties, but future products may be in-licensed from other sources. 
    Napo has partnerships with Glenmark Pharmaceuticals Limited of India and AsiaPharm Group Ltd. of China. For more information please
visit www.napopharma.com. 
    This announcement contains forward-looking statements relating to Napo Pharmaceuticals and its products that involve risks and
uncertainties, including statements regarding future products and developments that are not historical facts. Such statements are only
predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. These
statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should,'' "could,"
"project," "plan,'' "seek," "intend,'' or "anticipate'' or the negative thereof or comparable terminology and statements about industry
trends and Napo's future performance, operations and products. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCGUGGGUUPRGMA

Napo Pharm Di (LSE:NAPU)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Napo Pharm Di (LSE:NAPU)
Historical Stock Chart
Von Jun 2023 bis Jun 2024